Edition:
India

Cellectis SA (ALCLS.PA)

ALCLS.PA on Paris Stock Exchange

13.73EUR
9:05pm IST
Change (% chg)

€0.05 (+0.37%)
Prev Close
€13.68
Open
€13.60
Day's High
€13.88
Day's Low
€13.60
Volume
31,138
Avg. Vol
66,234
52-wk High
€26.44
52-wk Low
€11.97

Latest Key Developments (Source: Significant Developments)

Cellectis Reports Q1 Adjusted Loss Per Share $0.26
Wednesday, 8 May 2019 

May 7 (Reuters) - Cellectis SA ::CELLECTIS REPORTS FINANCIAL RESULTS FOR FIRST QUARTER 2019.Q1 ADJUSTED LOSS PER SHARE $0.26.Q1 LOSS PER SHARE $0.36.CASH POSITION OF $425 MILLION AS OF MARCH 31, 2019.STARTED CONSTRUCTION OF IN-HOUSE MANUFACTURING FACILITIES IMPACT AND SMART.  Full Article

Cellectis: FDA Clears UCARTCS1 IND Application
Wednesday, 3 Apr 2019 

April 3 (Reuters) - CELLECTIS SA ::SAID ON TUESDAY FDA CLEARS THE IND FOR UCARTCS1, THE FIRST ALLOGENEIC CAR-T TO TREAT MULTIPLE MYELOMA PATIENTS.FDA HAS APPROVED THE COMPANY'S IND APPLICATION TO INITIATE A PHASE 1 CLINICAL TRIAL FOR UCARTCS1, IN PATIENTS WITH MULTIPLE MYELOMA (MM).UCARTCS1 IS AN ALLOGENEIC, OFF-THE-SHELF, GENE-EDITED T-CELL PRODUCT CANDIDATE DESIGNED FOR THE TREATMENT OF MULTIPLE MYELOMA (MM)..UCART IS DESIGNED TO HAVE A LYMPHODEPLETING EFFECT, AND THE CAR T-CELL CROSS REACTION IS SUPPRESSED, ALLOWING FOR SUCCESSFUL MANUFACTURING..THE PHASE 1 OF THE MUNDI-01 STUDY IS DESIGNED TO ASSESS THE SAFETY AND TOLERABILITY AT INCREASING DOSE LEVELS OF UCARTCS1 IN PATIENTS LIVING WITH MM..  Full Article

Cellectis Q4 Operating Loss Widens To 29.3 Million Dollars
Tuesday, 12 Mar 2019 

March 12(Reuters) - CELLECTIS SA ::ANNOUNCED ON MONDAY, CELLECTIS REPORTS 4TH QUARTER AND FULL YEAR 2018 FINANCIAL RESULTS.CASH POSITION OF $452M AS OF DECEMBER 31, 2018 COMPARED TO $297M AS OF DECEMBER 31, 2017.CELLECTIS, THROUGH ITS NEW SUBSIDIARY CELLECTIS BIOLOGICS, INC., ENTERED INTO A LEASE AGREEMENT TO BUILD A MANUFACTURING FACILITY IN NORTH CAROLINA, ADVANCING COMMERCIALIZATION CAPABILITIES FOR ITS UCART PORTFOLIO.UCART123 IN PHASE 1 DOSE ESCALATION CLINICAL TRIAL ONGOING FOR AML.UCART22 RECEIVED FDA AND IRB APPROVALS FOR PHASE 1 DOSE ESCALATION CLINICAL TRIAL IN B-ALL PATIENTS.UCART19 ASH ABSTRACT BY PARTNERS SERVIER AND ALLOGENE SHOWED CONTINUED PROGRESS OF FIRST CLINICAL ALLOGENEIC CAR T-CELL PROGRAM FOR ALL ADULT AND PEDIATRIC PATIENTS.Q4 NET LOSS OF $26.1 MLN VS LOSS OF $28.7 MLN YEAR AGO.Q4 TOTAL REVENUE $3.1 MLN VS $6.9 MLN YEAR AGO.Q4 OPERATING LOSS OF $29.3 MLN VS LOSS OF $27.8 MLN YEAR AGO .  Full Article

Cellectis Operating Loss Widens To 21.7 Million US Dollars
Thursday, 2 Aug 2018 

Aug 2 (Reuters) - CELLECTIS SA ::SAID ON WEDNESDAY ITS Q2 REVENUES WERE $5.0 MLN VS $6.5 MLN YEAR AGO.Q2 OPERATING LOSS $21.7 MLN VS $19.9 MLN YEAR AGO.Q2 NET LOSS $9.7 MLN VS $26.5 MLN YEAR AGO.END-H1 CASH POSITION OF $491 MLN EXPECTED TO FUND OPERATIONS UNTIL 2022.  Full Article

Calyxt Announces Upsizing And Pricing Of Follow-On Offering
Friday, 18 May 2018 

May 18 (Reuters) - Calyxt Inc ::CALYXT ANNOUNCES UPSIZING AND PRICING OF FOLLOW-ON OFFERING.CALYXT - PRICE OF FOLLOW-ON PUBLIC OFFERING OF 3.6 MILLION SHARES OF COMMON STOCK LAUNCHED MAY 15 HAS BEEN SET AT $15.00 PER SHARE.CALYXT INC - OFFERING WAS UPSIZED FROM 3.1 MILLION SHARES TO ACCOMMODATE CELLECTIS TO BUY 550,000 SHARES.  Full Article

Cellectis Qtrly Total Revenues And Other Income $8.1 Mln Vs $10.3 Mln
Tuesday, 8 May 2018 

May 7 (Reuters) - Cellectis SA ::CELLECTIS SA QTRLY TOTAL REVENUES AND OTHER INCOME $8.1 MILLION VERSUS $10.3 MILLION.CELLECTIS SA QTRLY LOSS PER SHARE $0.71.CELLECTIS SA QTRLY ADJUSTED LOSS PER SHARE $0.39.  Full Article

Cellectis Announces Pricing Of Follow On Offering
Thursday, 5 Apr 2018 

April 5 (Reuters) - Cellectis SA ::CELLECTIS ANNOUNCES PRICING OF FOLLOW-ON OFFERING.‍PRICE OF ITS OFFERING OF ADS LAUNCHED ON APRIL 3, 2018, HAS BEEN SET TODAY AT $31.00/ADS AND NUMBER OF OFFERED ADSS IS 5.6 MILLION.  Full Article

Cellectis Announces Launch Of 175 Million Dollar Underwritten Public Offering Of Its American Depositary Shares
Wednesday, 4 Apr 2018 

April 4 (Reuters) - CELLECTIS SA ::ANNOUNCED ON WEDNESDAY LAUNCH OF FOLLOW-ON UNDERWRITTEN PUBLIC OFFERING OF $175 MLN OF ITS AMERICAN DEPOSITARY SHARES (ADS).EACH ADS REPRESENTS ONE ORDINARY SHARE OF CELLECTIS.TO GRANT UNDERWRITERS 30-DAY OPTION TO PURCHASE UP TO ADDITIONAL 15 PCT OF AGGREGATE OFFERING SIZE.GOLDMAN SACHS, CITIGROUP AND BARCLAYS ARE ACTING AS BOOK-RUNNING MANAGERS.NOMURA IS LEAD MANAGER, OPPENHEIMER AND LADENBURG THALMANN ARE CO-MANAGERS.  Full Article

Cellectis, Servier And Pfizer Present Preliminary Data From Two UCART19 Phase I Studies
Wednesday, 13 Dec 2017 

Dec 13 (Reuters) - CELLECTIS ::SERVIER AND PFIZER PRESENT PRELIMINARY DATA FROM UCART19 PHASE I STUDIES IN ADULT AND PEDIATRIC PATIENTS WITH ACUTE LYMPHOBLASTIC LEUKEMIA.STUDIES DEMONSTRATED SAFETY AND TOLERABILITY OF UCART19.STUDIES RESULTED IN 83-PCT COMPLETE REMISSION RATE ACROSS THE PATIENT POPULATION.IN 'CALM' TRIAL (UCART19 IN ADVANCED LYMPHOID MALIGNANCIES) FOR ADULTS, FIVE OUT OF SEVEN PATIENTS ACHIEVED MOLECULAR REMISSION AT DAY 28.'CALM' TRIAL: ONE GRADE 1 CUTANEOUS ACUTE GVHD OCCURED; NO SEVERE NEUROTOXICITY OBSERVED; CYTOKINE RELEASE SYNDROMES WERE MOSTLY MANAGEABLE.ONE PATIENT IN 'CALM' TRIAL DEVELOPED GRADE 4 CYTOKINE RELEASE SYNDROME AND NEUTROPENIC SEPSIS LEADING TO DEATH AT DAY 15.IN 'PALL' TRIAL (PEDIATRIC ACUTE LYMPHOBLASTIC LEUKEMIA) FOR CHILDREN, ALL FIVE PATIENTS ACHIEVED MOLECULAR REMISSION;.'PALL' TRIAL: ONE GRADE 1 CUTANEOUS ACUTE GVHD OCCURED; NO SEVERE NEUROTOXICITY OBSERVED.'PALL TRIAL': CYTOKINE RELEASE SYNDROMES WERE MOSTLY MANAGEABLE.  Full Article

Cellectis Appoints Stéphane Depil Senior VP Research & Development And Chief Medical Officer
Tuesday, 5 Dec 2017 

Dec 4 (Reuters) - CELLECTIS SA ::CELLECTIS APPOINTS IMMUNO-ONCOLOGY LEADER STÉPHANE DEPIL TO POSITION OF SENIOR VICE PRESIDENT RESEARCH & DEVELOPMENT AND CHIEF MEDICAL OFFICER.  Full Article

BRIEF-Cellectis Reports New CAR Design To Control T-Cells

* REPORTED ON MONDAY NEW CAR DESIGN TO CONTROL CAR T-CELLS IN NON-LETHAL WAY